NeuroSense Therapeutics Ltd. (NRSN) Stock Forecast
NRSN analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.33 / 5 from 3 analysts
- Price target
- $78.50 average of analyst targets
- Upside to target
- +2,457.0% from the latest close
- Next earnings
- —
- 52-week range
- $3.06 – $25.00
NRSN analyst ratings
3 analystsNumber of analysts at each rating.
NRSN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NRSN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$3.88 | −$4.45 | −$3.30 | −$8.80 | +56.0% | 2 |
| Next fiscal year (2027) | −$4.67 | −$7.12 | −$2.23 | −$3.88 | −20.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NRSN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Sep '26) | $0 | $0 | $0 | — | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $2.7M | $0 | $8.1M | 0.0% | 3 |
NRSN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NRSN revenue: reported and forecast
NRSN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$8.00 | −$8.00 | −$7.70 | −$6.22 | −$3.88 | −51.6% | 0 up · 0 down |
| Next fiscal year (2027) | −$16.40 | −$16.40 | −$13.50 | −$11.76 | −$4.67 | −71.5% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NRSN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NRSN beat in 10 of 12.
What analysts expect from NRSN
3 analysts cover NeuroSense Therapeutics; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $78.50, 2,457.0% above the latest close of $3.07. Analysts expect earnings of −$3.88 per share for 2026, +56.0% from a year earlier. For 2027 the average estimate is −$4.67 per share on revenue of $2.7 million. NeuroSense Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: NRSN income statement, NRSN key metrics, NRSN chart. See the NRSN stock overview for the latest quote and news.
NRSN forecast FAQ
What is NeuroSense Therapeutics's price target?
The average analyst price target for NeuroSense Therapeutics is $78.50, 2,457.0% above the latest close of $3.07.
Is NeuroSense Therapeutics a buy, hold or sell?
Of 3 analysts covering NeuroSense Therapeutics, 2 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is NeuroSense Therapeutics's EPS forecast?
Analysts forecast −$3.88 per share for 2026 (range −$4.45 to −$3.30); for 2027 the estimate is −$4.67.
Does NeuroSense Therapeutics usually beat earnings estimates?
NeuroSense Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.